RSV prophylaxis use in high-risk infants in Western Australia, 2002-2013: a record linkage cohort study

• Главные авторы: Ruomei Xu (Автор), Parveen Fathima (Автор), Tobias Strunk (Автор), Nicholas de Klerk (Автор), Thomas L. Snelling (Автор), Peter C. Richmond (Автор), Anthony D. Keil (Автор), Hannah C. Moore (Автор)
• Формат: ‌
• Опубликовано: BMC, 2020-10-01T00:00:00Z.
• Предметы: article
• Online-ссылка: Connect to this object online.

Abstract Background The monoclonal antibody, palivizumab is licensed for use in high-risk infants to prevent severe illness caused by respiratory syncytial virus (RSV). The level of its use and compliance with current jurisdictional guidelines which were amended in 2010, is unknown. We determined th...